Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101594885 Publication Model: Print Cited Medium: Internet ISSN: 2222-1751 (Electronic) Linking ISSN: 22221751 NLM ISO Abbreviation: Emerg Microbes Infect Subsets: MEDLINE
    • Publication Information:
      Publication: 2019- : [Philadelphia, PA] : Taylor & Francis
      Original Publication: New York : NPG, 2012-2018.
    • Subject Terms:
      COVID-19*/epidemiology ; COVID-19*/prevention & control ; Vaccines*; Child ; Adolescent ; Humans ; Infant, Newborn ; BNT162 Vaccine ; Case-Control Studies ; Hong Kong/epidemiology ; SARS-CoV-2 ; Hospitalization
    • Abstract:
      Severe COVID-19 appears to be disproportionately more common in children and adolescents since the emergence of Omicron. More evidence regarding vaccine effectiveness (VE) is urgently needed to assist policymakers in making decisions and minimize vaccine hesitancy among the public. This was a case-control study in the pediatric population using data extracted from the electronic health records database in Hong Kong. Individuals aged 3-17 with COVID-19 confirmed by polymerase chain reaction were included in the study. Each case was matched with up to 10 controls based on age, gender, and index date (within 3 calendar days). The VE of BNT162b2 and CoronaVac in preventing COVID-19, hospitalizations, and severe outcomes were estimated using conditional logistic regression adjusted by patients' comorbidities and medication history during the outbreak from January to August 2022. A total of 36,434 COVID-19 cases, 2231 COVID-19-related hospitalizations, and 1918 severe COVID-19 cases were matched to 109,004, 21,788, and 18,823 controls, respectively. Compared to the unvaccinated group, three doses of BNT162b2 or CoronaVac was associated with reduced risk of infection [VE: BNT162b2: 56.0% (95% CI: 49.6-61.6), CoronaVac: 39.4% (95% CI: 25.6-50.6)], hospitalization [VE: BNT162b2: 58.9% (95% CI: 36.1-73.6), CoronaVac: 51.7% (11.6-73.6)], and severe outcomes [VE: BNT162b2: 60.2% (95% CI: 33.7-76.1), CoronaVac: 42.2% (95% CI: -6.2-68.6)]. Our findings showed that three doses of BNT162b2 or CoronaVac was effective in preventing COVID-19, hospitalizations, and severe outcomes among the pediatric population during Omicron-dominant pandemic, which was further enhanced after a booster dose.
    • References:
      N Engl J Med. 2021 Dec 9;385(24):e83. (PMID: 34614327)
      MMWR Morb Mortal Wkly Rep. 2022 Mar 25;71(12):466-473. (PMID: 35324880)
      PLoS Med. 2022 Jun 21;19(6):e1004018. (PMID: 35727759)
      Cell. 2020 Nov 12;183(4):996-1012.e19. (PMID: 33010815)
      Lancet Healthy Longev. 2022 Jul;3(7):e491-e500. (PMID: 35813276)
      MMWR Morb Mortal Wkly Rep. 2021 Sep 10;70(36):1255-1260. (PMID: 34499627)
      Lancet Infect Dis. 2022 Jan;22(1):64-72. (PMID: 34411532)
      Ann Intern Med. 2022 Mar;175(3):362-370. (PMID: 35073155)
      Emerg Microbes Infect. 2020 Dec;9(1):2190-2199. (PMID: 32940572)
      Clin Infect Dis. 2022 Sep 10;75(4):673-681. (PMID: 34849657)
      BMJ. 2016 Feb 25;352:i969. (PMID: 26916049)
      J Hepatol. 2022 Nov;77(5):1339-1348. (PMID: 35817224)
      Science. 2022 Aug 19;377(6608):821-822. (PMID: 35981045)
      J Zhejiang Univ Sci B. 2014 Jan;15(1):58-66. (PMID: 24390745)
      Lancet Reg Health West Pac. 2022 Apr;21:100393. (PMID: 35128500)
      Lancet. 2022 Jul 9;400(10346):97-103. (PMID: 35780801)
      N Engl J Med. 2022 Jul 21;387(3):227-236. (PMID: 35767475)
      N Engl J Med. 2022 May 19;386(20):1899-1909. (PMID: 35353976)
      Am J Hematol. 2022 Apr;97(4):470-480. (PMID: 35080247)
      Thyroid. 2022 May;32(5):505-514. (PMID: 35216517)
      Kidney Int. 2022 Oct;102(4):922-925. (PMID: 35964798)
      Acta Paediatr. 2020 Jun;109(6):1088-1095. (PMID: 32202343)
      Ann Rheum Dis. 2022 Apr;81(4):564-568. (PMID: 34686479)
      J Autoimmun. 2022 Jun;130:102830. (PMID: 35461018)
      Nat Med. 2022 Jul;28(7):1377-1380. (PMID: 35605637)
      Emerg Microbes Infect. 2022 Dec;11(1):1742-1750. (PMID: 35730665)
      Nat Commun. 2022 Jan 20;13(1):411. (PMID: 35058463)
      N Engl J Med. 2022 Aug 11;387(6):525-532. (PMID: 35857701)
      EClinicalMedicine. 2022 Jun 25;50:101504. (PMID: 35770253)
      Emerg Microbes Infect. 2022 Dec;11(1):885-893. (PMID: 35254219)
      Cardiovasc Res. 2022 Jul 27;118(10):2329-2338. (PMID: 35732274)
      FASEB J. 2020 Oct;34(10):13877-13884. (PMID: 32856766)
      Nat Commun. 2022 Aug 13;13(1):4756. (PMID: 35963844)
    • Contributed Indexing:
      Keywords: COVID-19; inactivated vaccine; mRNA vaccine; pediatric population; vaccine effectiveness
    • Accession Number:
      0 (BNT162 Vaccine)
      0 (sinovac COVID-19 vaccine)
      0 (Vaccines)
    • Publication Date:
      Date Created: 20230228 Date Completed: 20230316 Latest Revision: 20230322
    • Publication Date:
      20231215
    • Accession Number:
      PMC10026771
    • Accession Number:
      10.1080/22221751.2023.2185455
    • Accession Number:
      36852582